Annual financial impact of well‐differentiated thyroid cancer care in the United States
Open Access
- 30 January 2014
- Vol. 120 (9), 1345-1352
- https://doi.org/10.1002/cncr.28562
Abstract
BACKGROUND Well‐differentiated thyroid cancer (WDTC) is a prevalent disease, which is increasing in incidence faster than any other cancer. Substantial direct medical care costs are related to the diagnosis and treatment of newly diagnosed patients as well as the ongoing surveillance of patients who have a long life expectancy. Prior analyses of the aggregate health care costs attributable to WDTC in the United States have not been reported. METHODS A stacked cohort cost analysis was performed on the US population from 1985 to 2013 to estimate the number of WDTC survivors in 2013. Incidence rates, and cancer‐specific and overall survival were based on Surveillance, Epidemiology, and End Results (SEER) data. Current and projected direct medical care costs attributable to the care of patients with WDTC were then estimated. Health care–related costs and event probabilities were based on Medicare reimbursement schedules and the literature. RESULTS Estimated overall societal cost of WDTC care in 2013 for all US patients diagnosed after 1985 is $1.6 billion. Diagnosis, surgery, and adjuvant therapy for newly diagnosed patients (41%) constitutes the greatest proportion of costs, followed by surveillance of survivors (37%), and nonoperative death costs attributable to thyroid cancer care (22%). Projected 2030 costs (in 2013 US dollars) based on current incidence trends exceed $3.5 billion. CONCLUSIONS Health care costs of WDTC are substantial. Unlike other cancers, the majority of the cost is incurred in the initial and continuing phases of care. With the projected increasing incidence, population, and survival trends, costs will continue to escalate. Cancer 2014;120:1345–1352. © 2014 American Cancer Society.Keywords
This publication has 39 references indexed in Scilit:
- National trends in thyroid surgery and the effect of volume on short‐term outcomesThe Laryngoscope, 2013
- Selective Use of Radioactive Iodine in Intermediate-Risk Papillary Thyroid CancerJAMA Otolaryngology–Head & Neck Surgery, 2012
- Estimating Risk of Recurrence in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation: Using Response to Therapy Variables to Modify the Initial Risk Estimates Predicted by the New American Thyroid Association Staging SystemThyroid®, 2010
- Frontiers in Thyroid Cancer: December 2009Thyroid®, 2009
- The National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference: a SummationCytojournal, 2008
- Cost-effective Management of Low-Risk Papillary Thyroid CarcinomaJAMA Otolaryngology–Head & Neck Surgery, 2007
- Projections of the costs associated with colorectal cancer care in the United States, 2000–2020Health Economics, 2007
- Increasing Incidence of Thyroid Cancer in the United States, 1973-2002JAMA, 2006
- Obtaining Long-Term Disease Specific Costs of CareMedical Care, 1999
- Differentiated Thyroid CancerArchives of Surgery, 1998